Journal article
Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: An 11-year follow-up of the CAP randomized clinical trial
B Schmidt, RS Roberts, PJ Anderson, EV Asztalos, L Costantini, PG Davis, D Dewey, J D'Ilario, LW Doyle, RE Grunau, D Moddemann, H Nelson, A Ohlsson, A Solimano, W Tin, J Dix, BA Adams, E Warriner, C Callanan, N Davis Show all
JAMA Pediatrics | Published : 2017
Abstract
IMPORTANCE: Caffeine citrate therapy for apnea of prematurity reduces the rates of bronchopulmonary dysplasia, severe retinopathy, and neurodevelopmental disability at 18 months and may improve motor function at 5 years. OBJECTIVE: To evaluate whether neonatal caffeine therapy is associated with improved functional outcomes 11 years later. DESIGN, SETTING, AND PARTICIPANTS: A follow-up study was conducted at 14 academic hospitals in Canada, Australia, and the United Kingdom from May 7, 2011, to May 27, 2016, of English- or French-speaking children who had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between October 11, 1999, and October 22, 2004..
View full abstractGrants
Awarded by Canadian Institutes of Health Research
Funding Acknowledgements
This follow-up study was supported by the Canadian Institutes of Health Research (MOP 102601).